Tim Brown: Schering-Plough Ahead

The big drugmaker has taken some knocks but will be back.
Publish date:

The biggest story in the National Football League this season is the biggest one from last season: the New York Giants.

The heavy underdogs beat Tom Brady and the New England Patriots 17-14 in one of the biggest upsets in Super Bowl history. Their Cinderella story is still being talked about heading into the 2008 season. The improbable ride they made to the championship should be inspiring to every other team in the NFL.

Think about it for just a second. Their all-time leading rusher Tiki Barber retired before the season. They were a wild-card team that played every single playoff game on the road. They were heavy underdogs in every game, but yet they were able to get it done.

If I were a head coach in the NFL, I would find a way to tell their story, even if I am on the staff of rivals the Washington Redskins, Philadelphia Eagles or Dallas Cowboys!

What's interesting is it looks as if the same pattern is happening again this year. Instead of losing their leading rusher, they have lost Michael Strahan, their all time leading sacker. So many are discounting the team as unable to defend the championship. It's dangerous business underestimating big leaguers, but it happens all the time in both sports and the market.

Today, I'm looking at a big-time company that also has been unfairly counted out. True, it has had its fair share of troubles -- most notably with its cholesterol drug Vytorin -- and will have challenges going forward. But I like this pick because I think its shares have a lot of upside potential.

I'm looking in



direction. The well-known drug developer is extremely undervalued in my eyes. And since its low point in early April, it has bounced back nicely and appears to be on the way back up.

The stock closed at $20.86 yesterday, well above the basement in its 52-week range of $13.83 to $33.40.

Plus, its efforts to diversify the company's moneymakers appear to be on track, according to CEO Fred Hassan. At the company's annual shareholder meeting in mid-May, Hassan said everything is on track. The idea behind the overhaul is to have between four and six primary products fueling growth. In the last four years, the company has almost doubled its sales and significantly beefed up the number of experimental drugs in the final phase of testing.

For us, this could be a great chance to go long.

As for the Giants, can they ride to glory again? If I were a betting man, I would not count them out.

Remember, keep moving the chains!

At the time of publication, Brown had no positions in stocks mentioned, although positions may change at any time.

Tim Brown played 16 seasons in the NFL, where he made nine Pro Bowls. After a brief stint with the Tampa Bay Buccaneers in 2004, Brown retired as an Oakland Raider. He was a Heisman Trophy winner in college for Notre Dame.